Business Development and Regulatory Affairs

The Business Development and Regulatory Affairs team at GID is responsible for driving strategic partnerships and collaborations to advance the cellular therapy aimed at alleviating knee osteoarthritis symptoms. They ensure compliance with regulatory requirements, oversee clinical trial readiness, and engage with stakeholders to facilitate smooth progression into pivotal Phase III trials, ultimately aiming to bring innovative treatments to market.